# Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status

> **NCT02339532** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 86 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** FEC100
- **DRUG:** Docetaxel
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02339532
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2019-10-07
- **Final completion:** 2024-07-08
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02339532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02339532, "Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02339532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*